Mokdad, Ali A.
Zhu, Hao
Beg, Muhammad S.
Arriaga, Yull
Dowell, Jonathan E.
Singal, Amit G.
Yopp, Adam C.
Funding for this research was provided by:
Peregrine Pharmaceuticals
Article History
First Online: 19 August 2019
Compliance with Ethical Standards
:
: This work was supported by Peregrine Pharmaceuticals, Inc.
: AAM, HZ, YA, JD, and ACY have no conflicts of interest that might be relevant to the contents of this manuscript. MSB has served in a consulting/advisory role for Cegene, Ipsen, Genentech/Roche, Guardant Health, and Boston Biomedical; on a speaker’s bureau for Ipsen, Genentech/Roche, and Bristol-Myers Squibb; and has received research funding from Gelgene, Bristol-Myers Squibb, AstraZeneca/MedImmune, Merk Serono, Agios, Five Prime Therapeutics, MedImuune, Tolero Pharmaceuticals, ArQule, Genetech, Sillajen, and CASI Pharmaceuticals. AGS has served in a consultant/advisory role for Eisai, Exelixis, Bayer, and BMS and on a speaker’s bureau for Bayer and BMS.